阶层血统追踪揭示了AML治疗耐药性的不同途径
Rachel Saxe1,2, Hannah Stuart1,3, Abigail Marshall1,2
1Molecular and Systems Biology, Dartmouth College, Hanover, NH.
bioRxiv : the preprint server for biology
|March 17, 2025
概括
癌细胞通过调整它们的基因构成来发展对治疗的抵抗力. 一种新的动态血统追踪方法FLARE揭示了AML细胞的特定适应和抵抗机制.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 癌细胞对抗癌疗法产生抵抗力,导致治疗失败.
- 了解治疗耐药性的演变对于开发有效的癌症疗法至关重要.
- 目前的技术在治疗压力下绘制癌症演变的地图上是有限的.
研究的目的:
- 开发和应用一种新的动态血统追踪方法,FLARE,以绘制治疗期间癌症演变的地图.
- 研究急性髓性白血病 (AML) 中的cytarabine (AraC) 耐药性的机制.
- 确定与AML治疗耐药性相关的细胞系和分子特征.
主要方法:
- 开发了FLARE (遵循血统适应和抵抗进化),一种层次,动态的血统追踪技术.
- 在Cytarabine (AraC) 暴露下,在体外和体内追踪AML细胞系进展.
- 分析了小鼠和人类AML细胞系,验证了TARGET-AML队列中的发现.
主要成果:
- 在AML中映射出明显的细胞系,表现出AraC持久性和/或耐药性.
- 在耐药AML细胞中发现了细胞粘附和运动途径的上调.
- 突出了免疫蛋白酶体11S调节帽子子子单元的遗传表达,作为一种生存机制.
- 在TARGET-AML队列中验证了阻力签名,在血液和骨髓中显示了不同的反应.
结论:
- FLARE是一种用于剖析癌症演变和治疗耐药性的新工具.
- 确定了特定的分子和细胞适应,推动AML对AraC的耐药性.
- 研究结果提供了对AML细胞生存,增殖和免疫逃生机制的见解.
- 揭示了与癌细胞显著的转录变化相关的广泛的抗药特征.
相关概念视频
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
01:21Lineage Commitment
3.0K
Commitment is the process whereby stem cells:
3.0K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
02:40Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K